Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amgen (NQ: AMGN )

261.01 -5.30 (-1.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,792,150
Open 264.04
Bid (Size) 260.08 (2)
Ask (Size) 261.50 (1)
Prev. Close 266.31
Today's Range 259.67 - 266.02
52wk Range 218.44 - 296.67
Shares Outstanding N/A
Dividend Yield 3.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns
The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ: 
Via Benzinga
Exposures Product Safety
Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration  
Via Benzinga

Performance

YTD
-0.24%
-0.24%
1 Month
+2.76%
+2.76%
3 Month
+16.00%
+16.00%
6 Month
+6.78%
+6.78%
1 Year
+13.27%
+13.27%

More News

Read More
Check Out What Whales Are Doing With AMGN
Via Benzinga
AskSlim Market Week - Friday, Sep. 29
Via Talk Markets
3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals
Via InvestorPlace
2 Dividend Growth Stocks to Buy Right Now
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
Via Benzinga
Amgen Unusual Options Activity
Via Benzinga
September's Shakeout: S&P 500, Nasdaq 100 See Just 13% Of Stocks Above 50-Day Average
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
Via Benzinga
Exposures Product Safety
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
AI To Revolutionize Clinical Trials And Diagnostics
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
Via Benzinga
2 Top Dividend Stocks to Buy in September
Via The Motley Fool
How Is The Market Feeling About Amgen?
Via Benzinga
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
Via FinancialNewsMedia
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Shares of Neumora Therapeutics Slumped This Week
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Flee to Healthcare Stocks if Recession Rears its Head?
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
3 Quality Dividend Stocks For A Bear Market
Via Talk Markets
Topics Economy
Exposures Economy
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
Via InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Via Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.